Evaxion A/S has taken a significant step by filing an amendment to its registration statement concerning a debt settlement agreement with the European Investment Bank (EIB). This action, filed on November 9, 2026, is crucial as it reflects the company’s ongoing efforts to strengthen its capital structure and improve financial flexibility.

Evaxion, a clinical-stage TechBio company, specializes in developing novel immunotherapies through its AI-Immunology™ platform. The amendment to the registration statement is particularly important as it relates to a previous debt settlement agreement finalized in July 2025, where EIB converted €3.5 million of its €7 million loan into equity via warrants.

Founded in Hoersholm, Denmark, Evaxion A/S operates under the SIC classification of Biological Products (No Diagnostic Substances). The company trades on Nasdaq under the ticker EVAX and is categorized as a non-accelerated filer and an emerging growth company.

The filing indicates that the registration statement, originally submitted in November 2025, is related solely to the potential resale of shares by EIB that are issuable upon the exercise of the warrants. Evaxion clarified that it is not conducting a capital raise and will not receive any proceeds from the sale of shares represented by American Depositary Shares (ADSs) by EIB.

According to the press release, Evaxion’s agreement with EIB has already provided a partial debt cancellation of €3.5 million, which has improved the company’s equity by $4.1 million. This strategic move has simplified Evaxion’s balance sheet, reduced overall liabilities, and enhanced cash flow.

The registration statement has not yet become effective, meaning that the securities cannot be sold or offered until it is approved. This filing may set a precedent for other companies in the biological products sector, as they navigate similar financial landscapes.

Looking ahead, Evaxion has not specified what actions will follow this filing. The company’s proactive approach in managing its debt and financial commitments could serve as a model for others in the industry facing financial challenges.